期刊
ARCHIVES OF CARDIOVASCULAR DISEASES
卷 106, 期 11, 页码 570-585出版社
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.acvd.2013.08.002
关键词
Heart failure; Incidence; Hospitalization; France; SNIIRAM
资金
- AstraZeneca
- Daiichi-Sankyo
- Eli Lilly
- GSK
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
- Servier
- Medicines Company
- Bayer
- Bristol-Myers Squibb
- Boehringer Ingelheim
- GlaxoSmithKline
- MSD-Schering
- Novo Nordisk
- Roche
- Abbott Vascular
- Menarini
- Merck Sharp Dohme
Background. - The incidence of heart failure (HF) is stable in industrialized countries, but its prevalence continues to increase, especially due to the ageing of the population, and mortality remains high. Objective. - To estimate the incidence in France and describe the management and short-term outcome of patients hospitalized for HF for the first time. Method. - The study population comprised French national health insurance general scheme beneficiaries (77% of the French population) hospitalized in 2009 with a principal diagnosis of HF after exclusion of those hospitalized for HF between 2006 and 2008 or with a chronic disease status for HE Data were collected from the national health insurance information system (SNIIRAM). Results. - A total of 69,958 patients (mean age 78 years; 48% men) were included. The incidence of first hospitalization for HF was 0.14% (>= 55 years, 0.5%; >= 90 years, 3.1%). Compared with controls without HF, patients more frequently presented cardiovascular or other co-morbidities. The hospital mortality rate was 6.4% and the mortality rate during the 30 days after discharge was 4.4% (3.4% without readmission). Among 30-day survivors, all-cause and HF 30-day readmission rates were 18% (<70 years, 22%; >= 90 years, 13%) and 5%, respectively. Reimbursements among 30-day survivors comprised at least a beta-blocker in 54% of cases, diuretics in 85%, angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in 67%, a diuretic and ACEI/ARB combination in 23% and a beta-blocker, ACEI/ARB and diuretic combination in 37%. Conclusion. - Patients admitted for HF presented high rates of co-morbidity, readmission and death at 30 days, and there remains room for improvement in their drug treatments; these findings indicate the need for improvement in return-home and therapeutic education programmes. (C) 2013 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据